A laser device

Abstract

The application provides a laser device, comprising: a laser emission assembly for emitting emitted laser of multiple wavelengths; a laser imaging feedback assembly for receiving feedback laser and generating an image of target tissue based on the feedback laser; a drug pushing assembly for pushing drugs; a transmission tube comprising, from inside to outside, a fiber core, a drug layer and a feedback fiber layer; wherein one end of the fiber core is connected with the laser emission assembly, and the other end is an emitted laser outlet end; the drug layer is formed as a ring-shaped channel, one end of which is connected with the drug pushing assembly, and the other end has a drug outlet; one end of the feedback fiber layer is connected with the laser imaging feedback assembly, and the other end is a feedback laser inlet end. Through the coaxial layered structure of the laser emission assembly, the laser imaging feedback assembly, the drug pushing assembly, the fiber core, the drug layer and the feedback fiber layer of the transmission tube, integrated integration of laser treatment, real-time imaging feedback and airflow drug delivery is realized.

Description

Technical Field

[0001] This application belongs to the field of laser technology, and in particular relates to a laser device. Background Technology

[0002] Current laser treatment equipment uses a single wavelength, limiting its treatment depth. Traditional single-wavelength lasers have a fixed penetration depth, making it difficult to simultaneously meet the needs of multi-level treatments such as superficial debridement, deep imaging, and mid-layer anti-inflammatory treatment. Furthermore, most devices rely on the doctor's visual inspection or intermittent imaging methods to assess treatment effectiveness, failing to provide real-time images of the treated area during treatment. Treatment often requires a step-by-step approach, increasing surgical time and the risk of infection.

[0003] Therefore, there is an urgent need for an intelligent laser device that integrates multi-wavelength combined therapy, real-time imaging feedback, and enhanced drug delivery. This device can also be used in scientific research and industrial fields. Summary of the Invention

[0004] This application provides a laser device, including a laser emitting component, a laser imaging feedback component, a transmission tube, and a drug delivery component; The laser emitting assembly is used to emit lasers of multiple wavelengths; The laser imaging feedback component is used to receive feedback laser light from the emitted laser on the irradiated target tissue and generate an image of the irradiated target tissue based on the feedback laser light. The drug propulsion assembly is used to store and utilize airflow to propel drugs; The transmission tube comprises, from the inside out, a fiber core, a drug layer, and a feedback fiber layer; wherein... One end of the fiber core is connected to the laser emitting assembly, and the other end is the laser emission outlet end, used to transmit the emitted laser to the target tissue; The drug layer is a ring-shaped channel, with one end connected to the drug delivery component and the other end having a drug outlet; One end of the feedback fiber layer is connected to the laser imaging feedback component, and the other end is the feedback laser inlet, used to transmit the received feedback laser to the laser imaging feedback component.

[0005] Furthermore, the annular channel is provided with isolated drug flow channels and clean gas flow channels; The drug flow channel is connected to the drug delivery component; The clean gas flow channel is connected to the gas pushing component and is used to blow clean gas to the laser emission outlet and the laser feedback inlet. Furthermore, the drug delivery component outputs drug and the gas delivery component outputs clean gas in a periodic alternation.

[0006] Furthermore, there are multiple drug flow channels and multiple cleaning gas flow channels, and the multiple drug flow channels and the multiple cleaning gas flow channels are arranged in parallel and spaced apart from each other; The orientation of the drug outlet of the drug flow channel is consistent with the centerline of the transfer tube; The clean gas outlet of the clean gas flow channel is provided with a first guide portion and a second guide portion that both protrude from the laser emission outlet end and the laser feedback inlet end; The first guide portion is located on the side close to the fiber core and has a first guide surface facing the feedback laser inlet end, the first guide surface being inclined outward; The second guide portion is located on the side near the feedback fiber layer, and it has a second guide surface facing the emitted laser exit end, the second guide surface being inclined inward; In the same clean gas outlet, the first guide portion and the second guide portion are arranged radially offset in the transmission pipe.

[0007] Furthermore, the transmission tube is connected to the laser emitting assembly and the drug propellant assembly via a connecting assembly; The connecting assembly includes a barrel-shaped component and a connector connected together; The open end of the barrel-shaped component is connected to the transmission tube, and a first optical fiber connection hole is provided at the center of one end with the bottom plate. The connector is tubular, with one end connected to the first optical fiber connection hole and the other end used to connect to the laser head of the laser emitting assembly; The base plate has multiple gas-liquid channels around the first optical fiber connection hole. One end of each gas-liquid channel is connected to the drug flow channel of the transmission tube, and the other end is used to connect to the drug output tube of the drug propulsion assembly. Multiple laser receivers are arranged circumferentially on the inner wall of the base plate, and the multiple laser receivers face the feedback fiber layer of the transmission tube. The base plate is provided with a second optical fiber connection hole, through which the signal lines of multiple laser receivers pass and connect to the laser imaging feedback component.

[0008] Furthermore, the device also includes a main control system, which is signal-connected to the laser emission component, the laser imaging feedback component, the transmission tube, and the drug propulsion component; The laser imaging feedback component includes a spectral domain optical coherence tomography unit, which is used to feed back the interference spectrum data of the laser and transmit it to the main control system; The main control system is used to process the interference spectral data to obtain a three-dimensional structural tomographic image and spectral absorption characteristics of the lesion region; based on the three-dimensional structural tomographic image and spectral absorption characteristics, it generates control signals to guide treatment decisions; and according to the control signals, it dynamically adjusts the output parameters of the laser emission component and / or the drug delivery parameters of the drug propulsion component.

[0009] Furthermore, the main control system processes the interference spectral data including: High-frequency interference modulation components are extracted from the interference spectral data and Fourier transform is performed to obtain depth information at each scanning point, and a three-dimensional tomographic image of the lesion is reconstructed. The low-frequency spectral envelope component of the interference spectral data was extracted and intensity integral analysis was performed in different bands to obtain the spectral absorption characteristics of each scanning point, including at least one physiological parameter among blood oxygen saturation, hemoglobin concentration and water content. The depth information is fused with the spectral absorption features to generate four-dimensional functional image data.

[0010] Furthermore, the main control system extracts the depth, area, and three-dimensional volume parameters of the lesion based on the three-dimensional structural tomography image, and extracts the quantitative distribution of blood oxygen saturation, hemoglobin concentration, and water content based on the spectral absorption characteristics, in order to provide a basis for treatment decisions.

[0011] Furthermore, the main control system controls the laser emitting component to select and output a treatment laser with a corresponding penetration depth based on the extracted lesion depth parameters: When the lesion depth is less than the first threshold, the first wavelength laser is output; When the lesion depth is greater than or equal to the first threshold, a second wavelength laser is output, wherein the wavelength of the second wavelength laser in the tissue is greater than the wavelength of the first wavelength laser.

[0012] Furthermore, the main control system dynamically adjusts the power density of the treatment laser based on the extracted blood oxygen saturation or hemoglobin concentration parameters: When the blood oxygen saturation is below the second threshold or the hemoglobin concentration is above the third threshold, the laser with the first power density is output. When the blood oxygen saturation rises above the second threshold or the hemoglobin concentration drops below the third threshold, the main control system controls the laser emission component to reduce to the second power density, wherein the first power density is greater than the second power density.

[0013] Furthermore, the main control system is also used to control the coordinated operation of the drug delivery component and the laser emission component, so that drug delivery and laser treatment can be carried out synchronously or asynchronously.

[0014] The above-described technical solution of the present invention has at least the following beneficial technical effects: This application achieves integrated laser therapy, real-time imaging feedback, and airflow-based drug delivery by setting up a coaxial layered structure of a laser emission component, a laser imaging feedback component, a drug propulsion component, and a transmission tube consisting of a fiber core, a drug layer, and a feedback fiber layer from the inside out. Each function works in tandem without interfering with the others. Attached Figure Description

[0015] To more clearly illustrate the technical solutions in the embodiments of this application or in the conventional technology, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0016] Figure 1 This is a schematic diagram of the transmission relationship of the laser device in one embodiment of this application; Figure 2 This is a schematic diagram of the transmission tube structure in one embodiment of this application; Figure 3 This is a schematic diagram of the structure of the drug flow channel and the cleaning gas flow channel in one embodiment of this application; Figure 4 This is a schematic diagram of the structure of the drug flow channel and the cleaning gas flow channel in another embodiment of this application; Figure 5 This is a schematic diagram of the structure of the connection component in one embodiment of this application; Figure 6 This is a schematic diagram of the connection component and the transmission tube in one embodiment of this application; Figure 7 This is a schematic diagram showing the separation of the connection component and the transmission tube in one embodiment of this application.

[0017] in, Figures 1 to 7 The correspondence between the reference numerals and component names in the attached drawings is as follows: 1-Transmission tube, 11-Fiber core, 12-Drug layer, 121-Drug flow channel, 122-Clean gas flow channel, 123-First guide section, 124-Second guide section; 13-Feedback fiber layer; 2-Connecting assembly, 21-Connector, 22-Barrel-shaped component, 221-Open end, 222-Gas-liquid channel, 223-First connecting hole, 224-Second connecting hole. Detailed Implementation

[0018] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the various embodiments of this application will be described in detail below with reference to the accompanying drawings. However, those skilled in the art will understand that many technical details are presented in the various embodiments of this application to facilitate a better understanding of the application. However, the technical solutions claimed in this application can be implemented even without these technical details and various variations and modifications based on the following embodiments. The division of the various embodiments below is for ease of description and should not constitute any limitation on the specific implementation of this application. The various embodiments can be combined with and referenced by each other without contradiction.

[0019] In one embodiment of this application, a laser device is provided; please refer to [link to relevant documentation]. Figure 1 As shown, the laser device includes a laser emitting component, a laser imaging feedback component, a transmission tube 1, a drug propulsion component, and a gas delivery component. The structure and function of each component are as follows: The laser emitting component is used to emit lasers of multiple wavelengths, ranging from 580nm to 1100nm, including bands such as 580nm, 650nm, 810nm, and 1064nm; and at least one of them is a pulsed laser, capable of penetrating ≥5mm into the target tissue. The laser emitting component allows for continuous stepless adjustment of the emitted laser, supporting independent single-wavelength output or combined multi-wavelength output, with the multi-wavelength output ratio continuously adjustable by the main control system. It can dynamically adjust the laser wavelength and power density according to instructions from the main control system to meet different treatment needs such as debridement, anti-inflammation, and repair, adapting to the treatment of lesions of different depths and states.

[0020] The laser imaging feedback component is used to receive feedback laser light from the emitted laser on the irradiated target tissue and generate an image of the irradiated target tissue based on the feedback laser light.

[0021] Preferably, the laser imaging feedback component includes a spectral domain optical coherence tomography unit, equipped with a spectrometer, a high-sensitivity optical detector such as a high-speed avalanche photodiode (APD), and can switch detection modes according to the treatment scenario; after processing, the interference spectrum data acquired by the spectral domain optical coherence tomography unit can simultaneously obtain the structural tomographic image and spectral feature information of the lesion area of ​​the target tissue; the laser imaging feedback component has a three-dimensional imaging resolution of ≤50μm for the target tissue and an imaging speed of ≥5 frames / second, which can efficiently capture feedback laser signals from superficial and deep lesions, ensuring the authenticity and integrity of the imaging data.

[0022] The drug propulsion component is used to store and utilize airflow to propel drugs. The stored drugs are single or combined formulations of antibacterial, anti-inflammatory, or repair-promoting drugs, with a particle size of less than 50 μm. The airflow pressure of the drug propulsion component is controlled at 0.1~0.3 MPa to ensure that drug powder does not deposit in the channel.

[0023] The connection between the transmission tube 1 and the laser emission assembly and drug delivery assembly adopts a quick-release interface, facilitating clinical replacement and adapting to the operational needs of confined spaces such as the oral cavity, nasal cavity, and ear. The transmission tube 1 comprises, from the inside out, a fiber core 11, a drug delivery layer 12, and a feedback fiber layer 13. These three layers are coaxially arranged, spatially independent, and respectively fulfill the functions of laser transmission, drug delivery, and laser reception. Figure 2 As shown, the specific structure of transmission tube 1 is as follows: Fiber core 11 is a solid optical fiber with a diameter of 100-5000μm. One end is connected to the laser emitting component, and the other end is the laser emission outlet, used for high-power, low-loss transmission of emitted lasers.

[0024] The drug layer 12 is located outside the fiber core 11, forming an annular channel parallel to the fiber core 11, with a cross-sectional area of ​​3 × 10⁻⁶. 3 ~5×10 3 μm 2 One end is connected to the drug propulsion component, and the other end has a drug outlet.

[0025] One end of the feedback fiber layer 13 is connected to the laser imaging feedback component, and the other end is the feedback laser inlet, used to efficiently capture the feedback laser reflected / scattered by the target tissue and transmit it back to the laser imaging feedback component. The feedback fiber layer 13 can be composed of multiple optical fibers.

[0026] In one embodiment of this application, such as Figure 3 As shown, the annular channel of the drug layer is equipped with a drug flow channel 121 and a cleaning gas flow channel 122 that are isolated from each other. The drug flow channel 121 is connected to the drug propulsion component, and the cleaning gas flow channel 122 is connected to the gas delivery component. The drug propulsion component adopts a pre-loaded drug delivery method. The gas delivery component can be a compressed air pump. The gas delivery component is connected to the cleaning gas flow channel 122 of the transmission pipe 1 and is used to spray cleaning gas to the laser emission outlet and the laser feedback inlet. The cleaning gas is sterile medical dry nitrogen or compressed air to avoid secondary contamination of the lesion tissue during the spraying process, and to prevent water vapor condensation from blocking the laser emission and reception. The gas output pressure and frequency of the gas delivery component are precisely controlled by the main control system to ensure the cleaning effect while avoiding excessive gas pressure that could damage nearby tissue.

[0027] Preferably, there are multiple drug flow channels 121 and multiple cleaning gas flow channels 122, and the multiple drug flow channels 121 and multiple cleaning gas flow channels 122 are arranged in parallel and spaced apart from each other. Optionally, the drug flow channels 121 and cleaning gas flow channels 122 can be straight or can be double (multiple) helices extending along the length direction of the fiber core 11.

[0028] Preferably, the orientation of the drug outlet of the drug channel 121 is consistent with the center line of the transmission tube 1, ensuring that the drug is accurately applied to the lesion area of ​​the laser-irradiated target tissue along the laser emission direction.

[0029] Preferably, see continue to see Figure 3 and Figure 4 The clean gas outlet of the clean gas flow channel 122 is provided with a first guide portion 123 and a second guide portion 124 that both protrude from the laser emission outlet end and the laser feedback inlet end.

[0030] The first guide portion 123 is located on the side close to the fiber core 11. It has a first guide surface facing the feedback laser inlet end. The first guide surface is inclined outward. The first guide surface can allow cleaning gas to be blown toward and clean the end face of the feedback laser inlet end of the outer feedback fiber layer 13.

[0031] The second guide section 124 is located on the side close to the feedback fiber layer 13. It has a second guide surface facing the laser emission outlet end. The second guide surface is inclined inward. The second guide surface can allow cleaning gas to be blown towards and clean the end face of the inner laser emission outlet end.

[0032] Preferably, when cleaning the target end face, in order to prevent the first guide surface and the second guide surface from blocking the guided cleaning gas, the first guide portion 123 and the second guide portion 124 are arranged radially offset in the same cleaning gas outlet (i.e., in different fan-shaped areas). Optionally, the projections of the first guide surface and the second guide surface on the cross-section of the transmission pipe 1 are spirally divergent to make the cleaning surface larger.

[0033] In one specific embodiment, such as Figure 6 and Figure 7 As shown, the transmission tube 1 is connected to the laser emission assembly and the drug propulsion assembly via the connecting assembly 2.

[0034] like Figure 5 As shown, the connecting component 2 includes a barrel-shaped member 22 and a connector 21 connected to each other.

[0035] The open end 221 of the barrel-shaped component 22 is connected to the transmission tube 1, and a first connecting hole 223 is provided at the center of the end with the base plate. The connector 21 is tubular, with one end connected to the first connecting hole 223 and the other end used to connect to the laser head of the laser emitting assembly; a fixing sleeve is provided on the outer side of the tubular connector 21, and the outer wall of the fixing sleeve is threaded for laser connection with the laser emitting assembly. Preferably, the connector 21 can be a commercially available SMA905 type fiber optic connector.

[0036] The bottom plate of the barrel-shaped component 22 has multiple gas-liquid channels 222 formed around the first connecting hole 223. One end of each gas-liquid channel 222 is connected to the drug flow channel 121 of the transmission tube 1, and the other end is used to connect to the drug output tube of the drug propulsion assembly. Specifically, one drug flow channel 121 is connected to one gas-liquid channel 222, and one clean gas flow channel 122 is connected to one gas-liquid channel 222. Multiple laser receivers are arranged circumferentially on the inner wall of the bottom plate, and the multiple laser receivers face the feedback fiber layer 13 of the transmission tube 1. The bottom plate has a second connecting hole 224, and the signal lines of the multiple laser receivers pass through the second connecting hole 224 to connect to the laser imaging feedback assembly.

[0037] In one embodiment, the outer wall of the drug layer 12 is longer than the outer wall of the feedback fiber layer 13 and extends outward to form an outwardly inclined slope, so as to ensure that the feedback laser is reflected to the laser receiver through the outside of the slope.

[0038] It should be noted that the present invention does not limit the type of laser in the laser emitting component. If it is a fiber laser, it can be directly connected to connector 21. If it is another type, such as a solid-state laser, the laser output end can be connected to a section of optical fiber through a coupler and then connected to connector 21.

[0039] In one embodiment of this application, the device further includes a main control system, which is electrically connected to the transmitting component, the laser imaging feedback component, the transmission tube 1, and the drug propulsion component; the processing procedure of the device includes: S1: The laser imaging feedback component includes a spectral-domain optical coherence tomography unit, used to acquire the interference spectral data I(k,x,y) of the feedback laser, where k is the wavenumber, corresponding to the wavelength λ; and (x,y) are the two-dimensional position coordinates of the scanning point. The interference spectral data contains high-frequency interference modulation components and low-frequency spectral envelope components. The high-frequency interference modulation components are generated by the interference between the reference light and the sample backscattered light, carrying tissue depth information; the low-frequency spectral envelope components are determined by the tissue's absorption and scattering characteristics of light of different wavelengths, carrying tissue physiological function information.

[0040] S2: The main control system performs joint analysis on the interference spectral data I(k) of each scanning point, and simultaneously extracts structural information and functional information in parallel.

[0041] S21: Extract the high-frequency interference modulation components from the interference spectral data. Perform a Fourier transform on the high-frequency modulation components to obtain the reflection intensity distribution of the scan point in the depth direction, i.e., the A-scan signal A(z). A(z) reflects the structural information of the tissue or lesion at different depths from the surface to the deep layers, such as the reflection intensity and scattering characteristics of each layer boundary. Combine the A-scan signals of all (x,y) scan points to obtain a three-dimensional structural tomographic image V(x,y,z) of the lesion region through a three-dimensional reconstruction algorithm. This three-dimensional structural image contains structural information such as the spatial location, morphological contour, boundary range, and depth distribution of the lesion. Call the pre-trained 3DU-Net model, input V(x,y,z), and output a lesion probability map. Threshold the probability map, for example, if the probability is >0.5, generate a binary mask B(x,y,z), where 1 represents a lesion and 0 represents normal.

[0042] S22: Extract the low-frequency spectral envelope component from the interference spectral data, i.e., the spectral intensity distribution after removing high-frequency interference fringes.

[0043] Intensity integral analysis of the low-frequency spectral envelope at different characteristic bands was performed to obtain the spectral absorption characteristic S(λ) of that scan point. This spectral absorption characteristic includes at least blood oxygen saturation, hemoglobin concentration, and water content. Specifically, blood oxygen saturation was calculated by analyzing the absorption difference between oxyhemoglobin and deoxyhemoglobin in the 760 nm and 850 nm bands. Hemoglobin concentration was calculated by analyzing the intensity of the characteristic absorption peaks of hemoglobin at 540 nm and 570 nm. Water content was calculated by analyzing the intensity of the absorption peak of water molecules at 980 nm. These spectral absorption characteristics directly reflect the physiological state of tissues, such as the degree of inflammation, congestion, and edema.

[0044] S3: The main control system fuses depth information with spectral features to directly construct four-dimensional functional image data F(x,y,z,λ). For each scan point (x,y), its depth direction information A(z) and spectral feature S(λ) are obtained simultaneously, without any time difference or spatial displacement. At each spatial location point (x,y,z) in the tissue or lesion area, the four-dimensional functional image data corresponds to a complete set of spectral feature information, including physiological parameters such as blood oxygen saturation, hemoglobin concentration, and water content at that point.

[0045] S4: Extract quantitative parameters from four-dimensional functional image data, including: re-extracting the maximum lesion depth, lesion surface area, lesion three-dimensional volume, and lesion boundary information from three-dimensional structural tomography images. Extracting specific spatial distributions of blood oxygen saturation reflecting the degree of inflammatory activity in different regions and depths, hemoglobin concentration reflecting the degree of congestion in different regions, and water content reflecting the degree of edema in different regions from the spectral dimension S(λ).

[0046] S5: The main control system dynamically adjusts the treatment parameters according to the quantitative parameters extracted above and the preset control logic.

[0047] Preferably, the main control system controls the laser emitting component to select and output a treatment laser with a corresponding penetration depth based on the extracted lesion depth parameters: When the lesion depth is less than the first threshold, it indicates that the inflammation is mainly confined to the superficial layer, and the first wavelength of laser light is selected. For example, the first wavelength of laser light is 650nm red light or 580nm yellow light. These wavelengths have a shallow penetration depth in tissues, and the energy is mainly deposited in the superficial layer, achieving precise superficial treatment and avoiding damage to deeper healthy tissues. The first threshold needs to be determined based on the actual type of lesion examined by medical staff beforehand.

[0048] When the lesion depth is greater than or equal to the first threshold, it indicates that the inflammation has invaded deep tissues, and the system selects to output a second wavelength laser. For example, the second wavelength laser is an 810nm or 1064nm near-infrared laser. This type of wavelength has a greater penetration depth in tissues than the first wavelength laser, and can effectively deliver treatment energy to deep lesions.

[0049] Preferably, the main control system dynamically adjusts the power density of the treatment laser based on the extracted blood oxygen saturation or hemoglobin concentration parameters: Initial high-dose treatment phase: When blood oxygen saturation is below the second threshold or hemoglobin concentration is above the third threshold, it indicates active inflammation and severe congestion in the area, requiring strong treatment energy. A high-dose, first-power-density laser is delivered to rapidly ablate the inflamed tissue.

[0050] Real-time monitoring and de-escalation phase: As treatment progresses, the main control system continuously monitors parameter changes. When blood oxygen saturation rises above the second threshold or hemoglobin concentration falls below the third threshold, it indicates that inflammation has been effectively controlled. The system automatically reduces to the second power density (lower dose) to avoid overtreatment. The second threshold can be 70% (below this value indicates severe inflammation), and the third threshold can be 85% (below this value indicates inflammation relief). The first power density can be 6-9 J / cm³. 2 Suitable for severe inflammation, the second power density can be 1-3 J / cm³. 2 Suitable for mild inflammation.

[0051] Preferably, the main control system is also used to control the coordinated operation of the drug delivery component and the laser emission component: Optionally, laser treatment and drug delivery are performed simultaneously, utilizing the thermal or photochemical effects of the laser to enhance drug penetration and absorption in tissues. Optionally, depending on treatment needs, laser treatment can be performed first, followed by drug delivery, such as ablating necrotic tissue before spraying repair drugs; or drug delivery can be performed first, followed by laser treatment, such as drug sensitization followed by laser activation. Optionally, the main control system controls the cleaning gas channel 122 to spray clean gas during the drug delivery cycle intervals to keep the fiber end face clean, ensuring stable output of the therapeutic laser and high-quality reception of imaging signals.

[0052] Preferably, the laser imaging feedback component acquires interference spectral data in real time at a rate of ≥5 frames / second. The main control system updates the four-dimensional functional image and quantitative parameters in real time.

[0053] When the rate of change of parameters in a certain area is detected to be lower than expected, the laser power density in that area is automatically increased or the irradiation time is extended. When a certain area is detected to have reached the treatment endpoint (e.g., depth less than the fourth threshold, normal blood oxygenation, and spectrum close to normal tissue), the laser output in that area is automatically stopped.

[0054] Preferably, the preset treatment modes include at least three: debridement mode, anti-inflammatory mode, and repair mode. The mode automatically switches based on the lesion analysis results from the laser imaging feedback component. In debridement mode, a high-power-density pulsed laser is output to achieve precise ablation of the lesion tissue. In anti-inflammatory mode, a medium-power-density multi-wavelength laser is output, working in conjunction with anti-inflammatory drugs to achieve synergistic anti-inflammatory effects. In repair mode, a low-power-density pulsed laser is output, working in conjunction with repair-promoting drugs to promote tissue regeneration in the lesion wound.

[0055] Preferably, the built-in data recording and wireless transmission module can record lesion imaging data, treatment parameters, dynamic changes in the course of the disease, and other information in real time, and synchronize them to external terminal devices such as doctor workstations and mobile terminals, so as to realize digital traceability, remote monitoring and data management of the treatment process; Preferably, the generated four-dimensional functional image data is used as the core basis for treatment decisions, to accurately define lesion boundaries, distinguish lesions from normal tissue, determine treatment endpoints, and assess wound repair progress, thus providing data support for personalized treatment.

[0056] It should be understood that the specific embodiments described above are merely illustrative or explanatory of the principles of this application and do not constitute a limitation thereof. Therefore, any modifications, equivalent substitutions, improvements, etc., made without departing from the spirit and scope of this application should be included within the protection scope of this application. Furthermore, the appended claims are intended to cover all variations and modifications falling within the scope and boundaries of the appended claims, or equivalent forms of such scope and boundaries.

Claims

1. A laser device, characterized in that, It includes a laser emitting assembly, a laser imaging feedback assembly, a transmission tube (1), and a drug propulsion assembly; The laser emitting assembly is used to emit lasers of multiple wavelengths; The laser imaging feedback component is used to receive feedback laser light from the emitted laser on the irradiated target tissue and generate an image of the irradiated target tissue based on the feedback laser light. The drug propulsion assembly is used to store and utilize airflow to propel drugs; The transmission tube (1) comprises, from the inside out, a fiber core (11), a drug layer (12), and a feedback fiber layer (13); wherein, One end of the fiber core (11) is connected to the laser emitting assembly, and the other end is the laser emission outlet end, used to transmit the emitted laser to the target tissue; The drug layer (12) is a ring-shaped channel, one end of which is connected to the drug propulsion assembly, and the other end has a drug outlet; One end of the feedback fiber layer (13) is connected to the laser imaging feedback component, and the other end is the feedback laser inlet, which is used to transmit the received feedback laser to the laser imaging feedback component.

2. The laser device according to claim 1, characterized in that, The annular channel is provided with a drug flow channel (121) and a clean gas flow channel (122) that are isolated from each other. The drug flow channel (121) is connected to the drug propulsion assembly; The clean gas flow channel (122) is connected to the gas pushing component and is used to spray clean gas to the laser emission outlet and the laser feedback inlet.

3. The laser device according to claim 2, characterized in that, The drug delivery component outputs drug and the gas delivery component outputs clean gas in a periodic alternation.

4. The laser device according to claim 2, characterized in that, There are multiple drug flow channels (121) and multiple clean gas flow channels (122), and the multiple drug flow channels (121) and the multiple clean gas flow channels (122) are arranged in parallel and at intervals. The orientation of the drug outlet of the drug flow channel (121) is consistent with the centerline of the transfer tube (1); The clean gas outlet of the clean gas channel (122) is provided with a first guide portion (123) and a second guide portion (124) that both protrude from the laser emission outlet end and the laser feedback inlet end. The first guide portion (123) is located on the side close to the fiber core (11), and has a first guide surface facing the feedback laser inlet end, the first guide surface being inclined outward; The second guide portion (124) is located on the side close to the feedback fiber layer (13), and has a second guide surface facing the laser emission outlet end, the second guide surface being inclined inward; In the same clean gas outlet, the first guide (123) and the second guide (124) are arranged radially offset in the transmission pipe (1).

5. The laser device according to claim 2, characterized in that, The transmission tube (1) is connected to the laser emission assembly and the drug delivery assembly via a connecting assembly (2); The connecting assembly (2) includes a barrel-shaped member (22) and a connector (21) connected to each other; The open end (221) of the barrel-shaped component (22) is connected to the transmission pipe (1), and a first connection hole (223) is provided at the center of one end with a bottom plate. The connector (21) is tubular, with one end connected to the first connecting hole (223) and the other end used to connect to the laser head of the laser emitting assembly; The base plate has multiple gas-liquid channels (222) around the first connecting hole (223). One end of the gas-liquid channel (222) is connected to the drug flow channel (121) of the transmission pipe (1), and the other end is used to connect to the drug output pipe of the drug propulsion assembly. Multiple laser receivers are arranged circumferentially on the inner wall of the base plate, and the multiple laser receivers face the feedback fiber layer (13) of the transmission tube (1). The base plate is provided with a second connection hole (224), through which the signal lines of multiple laser receivers pass and are connected to the laser imaging feedback component.

6. The laser device according to claim 1, characterized in that, It also includes a main control system, which is signal-connected to the laser emission assembly, laser imaging feedback assembly, transmission tube (1) and drug propulsion assembly; The laser imaging feedback component includes a spectral domain optical coherence tomography unit, which is used to acquire the interference spectrum data of the feedback laser and transmit it to the main control system; The main control system is used to process the interference spectral data to obtain a three-dimensional structural tomographic image and spectral absorption characteristics of the lesion region; Based on the three-dimensional structural tomography image and spectral absorption characteristics, control signals are generated to guide treatment decisions. The output parameters of the laser emitting component and / or the drug delivery parameters of the drug propulsion component are dynamically adjusted according to the control signal.

7. The laser device according to claim 6, characterized in that, The main control system processes the interference spectral data including: High-frequency interference modulation components are extracted from the interference spectral data and Fourier transform is performed to obtain depth information at each scanning point, and a three-dimensional tomographic image of the lesion is reconstructed. The low-frequency spectral envelope component of the interference spectral data was extracted and intensity integral analysis was performed in different bands to obtain the spectral absorption characteristics of each scanning point, including at least one physiological parameter among blood oxygen saturation, hemoglobin concentration and water content. The depth information is fused with the spectral absorption features to generate four-dimensional functional image data.

8. The laser device according to claim 7, characterized in that, The main control system extracts the depth, area, and three-dimensional volume parameters of the lesion based on the three-dimensional structural tomography image, and extracts the quantitative distribution of blood oxygen saturation, hemoglobin concentration, and water content based on the spectral absorption characteristics.

9. The laser device according to claim 8, characterized in that, The main control system controls the laser emitting component to select and output a treatment laser with a corresponding penetration depth based on the extracted lesion depth parameters: When the lesion depth is less than the first threshold, the first wavelength laser is output; When the lesion depth is greater than or equal to the first threshold, a second wavelength laser is output, wherein the wavelength of the second wavelength laser is greater than the wavelength of the first wavelength laser.

10. The laser device according to claim 8, characterized in that, The main control system dynamically adjusts the power density of the treatment laser based on the extracted blood oxygen saturation or hemoglobin concentration parameters. When the blood oxygen saturation is below the second threshold or the hemoglobin concentration is above the third threshold, the laser with the first power density is output. When the blood oxygen saturation rises above the second threshold or the hemoglobin concentration drops below the third threshold, the main control system controls the laser emission component to reduce to the second power density, wherein the first power density is greater than the second power density.

Images